ZYDUSLIFE

Gains Momentum Post USFDA Green Light for Cholesterol Drug

has received final USFDA approval for Niacin Extended-Release Tablets (500/750/1000 mg), targeting cholesterol and triglyceride reduction. The drug has U.S. annual sales of $5.5M and will be produced at their Ahmedabad unit. 🔍 Fundamentals Snapshot: 🏢 Market Cap: ₹89,937 Cr 📊 Promoter Holding: 74.99% 📈 52-Week High/Low: ₹1323.90 / ₹797.05 ✅ Total ANDA Approvals: 425 🧪 Integrated pharma player with R&D to distribution presence 📌 Watch for further momentum as strong regulatory approvals and stable fundamentals may support the stock’s next move.